Education
About Us
Working with TipRanks
Follow Us
Camurus AB (SE:CAMX)
:CAMX
CAMX Stock Chart & Stats
kr665.00
-kr17.00(-2.71%)
At close: 4:00 PM EST
kr665.00
-kr17.00(-2.71%)
Day’s Range― - ―
52-Week Rangekr483.80 - kr754.50
Previous CloseN/A
Volume19.01K
Average Volume (3M)126.83K
Market Cap
kr30.84B
Enterprise Valuekr28.14B
Total Cash (Recent Filing)kr3.73B
Total Debt (Recent Filing)kr106.03M
Price to Earnings (P/E)41.5
Beta0.77
Next Earnings
May 12, 2026EPS Estimate
3.54Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.67
Shares Outstanding59,880,184
10 Day Avg. Volume148,560
30 Day Avg. Volume126,834
Financial Highlights & Ratios
PEG Ratio0.73
Price to Book (P/B)8.62
Price to Sales (P/S)16.11
P/FCF Ratio49.93
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained gross margins near 89–93% provide durable operating leverage and margin resilience across core products. High, stable gross margins support profitability even if sales fluctuate, enabling reinvestment into launches and R&D without immediate margin erosion.
Strong Cash GenerationRobust operating cash flow and large free cash flow give the company financial flexibility to fund U.S. commercial expansion, late‑stage programs and milestones without heavy reliance on external financing. Improved cash conversion supports sustainable investment and downside protection.
Regulatory & Launch CatalystsRegulatory approvals and an accepted NDA with a set PDUFA date materially expand addressable markets and create structural revenue diversification. Successful U.S. approval and EU launches shift the company from single-product concentration toward multi-market commercial execution.
Bears Say
Market-access & Reimbursement ConstraintsStructural reimbursement, funding and physician-remuneration barriers in large European markets limit uptake of the core Buvidal franchise. These systemic access issues suppress long-term revenue potential in major markets and slow the pace at which approvals convert to meaningful sales.
Revenue VolatilityInconsistent top-line trends—despite strong margins—reduce predictability of earnings and cash flow. Periods of negative or volatile revenue increase reliance on milestone timing and new launches to sustain growth, complicating capital allocation and long-term planning.
Milestone & Event Timing UncertaintyDependence on milestone payments and event-driven readouts creates structural timing risk: missed or delayed milestones compress near-term cash inflows and make medium-term revenue projections contingent on external partner actions and event accrual rates.
Camurus AB News
CAMX FAQ
What was Camurus AB’s price range in the past 12 months?
Camurus AB lowest stock price was kr483.80 and its highest was kr754.50 in the past 12 months.
What is Camurus AB’s market cap?
Camurus AB’s market cap is kr30.84B.
When is Camurus AB’s upcoming earnings report date?
Camurus AB’s upcoming earnings report date is May 12, 2026 which is in 79 days.
How were Camurus AB’s earnings last quarter?
Camurus AB released its earnings results on Feb 12, 2026. The company reported kr1.67 earnings per share for the quarter, missing the consensus estimate of kr2.367 by -kr0.697.
Is Camurus AB overvalued?
According to Wall Street analysts Camurus AB’s price is currently Overvalued.
Does Camurus AB pay dividends?
Camurus AB does not currently pay dividends.
What is Camurus AB’s EPS estimate?
Camurus AB’s EPS estimate is 3.54.
How many shares outstanding does Camurus AB have?
Camurus AB has 59,880,184 shares outstanding.
What happened to Camurus AB’s price movement after its last earnings report?
Camurus AB reported an EPS of kr1.67 in its last earnings report, missing expectations of kr2.367. Following the earnings report the stock price went down -24.03%.
Which hedge fund is a major shareholder of Camurus AB?
Currently, no hedge funds are holding shares in SE:CAMX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Camurus AB
Camurus AB (publ), a pharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, Japan, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence; episil oral liquid, a medical device for the treatment of inflammatory and painful conditions in the oral cavity; and Brixadi to treat opioid use disorder Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; CAM2047 for the treatment of chemotherapy-induced nausea and vomiting that is in phase 1 clinical trial; and CAM2048, which is in phase I clinical trial for postoperative pain. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.
CAMX Company Deck
CAMX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a broadly positive strategic and financial picture for Camurus: full-year revenue and operating profitability improved materially, net cash increased significantly, regulatory approvals and U.S. FDA acceptance (PDUFA set) support upcoming launches, Brixadi royalties showed strong growth, and early-stage R&D (CAM2056) delivered compelling data. At the same time, the company faces notable short-term headwinds: Q4 revenue and product sales were down due to a U.K. distribution change and FX effects, quarter operating profit contracted, access/reimbursement barriers in several large European markets constrain Buvidal upside, and timing uncertainty remains for the SORENTO readout and some milestone revenues. Management provided constructive 2026 guidance while flagging planned increases in OpEx tied to U.S. launch preparation. Overall, strengths in commercial traction, cash position, approvals, and pipeline momentum outweigh the near-term operational and market-access challenges.View all SE:CAMX earnings summariesTechnical Analysis
Hansa Biopharma AB
―
BioInvent International AB
―
BioArctic AB Class B
―
Vicore Pharma Holding AB
―
Xspray Pharma AB
―
Options Prices
Currently, No data available
---